Soluble yeast beta-1,3/1,6-glucan - paediatric investigation plan

soluble yeast beta-1,3/1,6-glucan

Key facts

• Active substance:
  soluble yeast beta-1,3/1,6-glucan
• Therapeutic area:
  Endocrinology-Gynaecology-Fertility-Metabolism
• Decision number:
  P/221/2009
• PIP number:
  Soluble yeast beta-1,3/1,6-glucan
• Pharmaceutical form(s):
  Cutaneous solution
• Condition(s) / indication(s):
  Treatment of diabetic foot ulcer
• Route(s) of administration:
  Cutaneous use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  03/11/2009
• Compliance check done:
  No

Decision

P/221/2009: European Medicines Agency Decision of 3 November 2009 on the granting of a product specific waiver for soluble yeast beta-1,3/1,6-glucan EMEA-000633-PIP01-09) in accordance with Regulation (EC) No 1901/2006 o...

Adopted Reference Number: EMEA/687790/2009